Amgen has reported positive phase 3 results ... for additional indications on Soliris' label like generalised myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD).

Amgen is preparing to file a third indication for Uplizna, as a twice-yearly therapy for generalised myasthenia gravis, following new phase 3 data.

Dr Nicholas Silvestri looks ahead to new data on existing agents and emerging therapies for myasthenia gravis.

Dr Nicholas Silvestri shares AAN 2025 highlights, including anticipated presentations, quick takeaways, and insights on the ...

highlighting the Company's innovative autoantibody disease research and the potential of nipocalimab to provide long-term sustained disease control in the treatment of generalized myasthenia ...

First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for Immutep Global Phase III with efti will enrol approximately 756 patients at more than ...

After hours: 21 March at 7:58:05 pm GMT-4 Loading Chart for AMGN ...

Pre-Market: 8:59:48 a.m. EDT Loading Chart for AMGN ...